Market revenue in 2023 | USD 449.1 million |
Market revenue in 2030 | USD 791.6 million |
Growth rate | 8.4% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 81.67% in 2023. Horizon Databook has segmented the Latin America hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
The Latin America hereditary testing market is anticipated to grow at a lucrative pace during the forecast period. Latin America has the most genetically admixed population across the world and its combinations of genetic ancestries have hugely impacted on genomic determinants of several genetic diseases.
Among these diseases, breast cancer is the most common malignancy and the leading cause of cancer-related mortality in Latin America. To combat this, a network of collaborators and cancer specialists have combined to establish a Latin American consortium for HBOC-LACAM.
This study involves investigation of genetic susceptibility to breast cancer in Latin America, focusing mainly on inherited cases. It gathers a group of researchers from Colombia, Guatemala, Argentina, Peru, and Mexico to study hereditary breast cancer cases.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America hereditary testing market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account